CymaBay Therapeutics Inc (NASDAQ:CBAY) Shares Bought by Vivo Capital LLC

Vivo Capital LLC increased its stake in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 13.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 906,000 shares of the biopharmaceutical company’s stock after acquiring an additional 106,000 shares during the period. CymaBay Therapeutics comprises approximately 1.6% of Vivo Capital LLC’s investment portfolio, making the stock its 18th largest holding. Vivo Capital LLC owned 1.54% of CymaBay Therapeutics worth $12,158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. BlackRock Inc. grew its position in shares of CymaBay Therapeutics by 246.8% in the second quarter. BlackRock Inc. now owns 4,054,285 shares of the biopharmaceutical company’s stock valued at $54,410,000 after purchasing an additional 2,885,082 shares during the last quarter. Redmile Group LLC lifted its stake in shares of CymaBay Therapeutics by 47.6% in the 1st quarter. Redmile Group LLC now owns 2,955,565 shares of the biopharmaceutical company’s stock valued at $38,393,000 after acquiring an additional 953,300 shares during the last quarter. Eagle Asset Management Inc. bought a new position in shares of CymaBay Therapeutics in the 2nd quarter valued at $27,686,000. Citadel Advisors LLC lifted its stake in shares of CymaBay Therapeutics by 79.2% in the 2nd quarter. Citadel Advisors LLC now owns 1,914,807 shares of the biopharmaceutical company’s stock valued at $25,696,000 after acquiring an additional 846,407 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of CymaBay Therapeutics by 24.2% in the 1st quarter. Franklin Resources Inc. now owns 1,798,700 shares of the biopharmaceutical company’s stock valued at $23,365,000 after acquiring an additional 350,000 shares during the last quarter. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Sujal Shah acquired 5,000 shares of the stock in a transaction dated Friday, July 27th. The stock was purchased at an average cost of $10.90 per share, with a total value of $54,500.00. Following the completion of the purchase, the chief executive officer now owns 95,000 shares in the company, valued at approximately $1,035,500. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.50% of the company’s stock.

CymaBay Therapeutics stock opened at $12.69 on Friday. CymaBay Therapeutics Inc has a twelve month low of $6.75 and a twelve month high of $15.59.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). equities analysts forecast that CymaBay Therapeutics Inc will post -1.19 EPS for the current fiscal year.

CBAY has been the subject of several research reports. Zacks Investment Research downgraded CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Raymond James initiated coverage on CymaBay Therapeutics in a research note on Thursday, June 28th. They issued an “outperform” rating and a $20.00 target price for the company. BidaskClub upgraded CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 15th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target (up previously from $21.00) on shares of CymaBay Therapeutics in a research report on Wednesday, June 6th. Finally, Piper Jaffray Companies raised their price target on shares of CymaBay Therapeutics to $30.00 and gave the company an “overweight” rating in a research report on Friday, August 10th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.88.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Further Reading: Technical Analysis of Stocks, How Can It Help

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply